Wagner Wealth Management LLC acquired a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 684 shares of the medical instruments supplier’s stock, valued at approximately $154,000.
A number of other hedge funds have also recently bought and sold shares of BDX. D.B. Root & Company LLC purchased a new stake in shares of Becton Dickinson and in the fourth quarter worth approximately $723,000. Colonial Trust Advisors lifted its position in shares of Becton Dickinson and by 7.3% in the fourth quarter. Colonial Trust Advisors now owns 3,440 shares of the medical instruments supplier’s stock worth $736,000 after purchasing an additional 235 shares in the last quarter. Penbrook Management LLC purchased a new stake in shares of Becton Dickinson and in the fourth quarter worth approximately $888,000. Xact Kapitalforvaltning AB lifted its position in shares of Becton Dickinson and by 25.3% in the fourth quarter. Xact Kapitalforvaltning AB now owns 37,285 shares of the medical instruments supplier’s stock worth $7,981,000 after purchasing an additional 7,534 shares in the last quarter. Finally, CNB Bank purchased a new stake in shares of Becton Dickinson and in the fourth quarter worth approximately $500,000. 83.35% of the stock is owned by institutional investors.
A number of research firms have recently issued reports on BDX. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Citigroup raised shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. Zacks Investment Research lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Morgan Stanley raised their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Finally, BMO Capital Markets initiated coverage on shares of Becton Dickinson and in a research report on Monday, March 5th. They set a “market perform” rating and a $249.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $238.00.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the company posted $2.33 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. equities research analysts forecast that Becton Dickinson and Co will post 10.94 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.42%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Timothy M. Ring sold 176 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the transaction, the director now owns 170,688 shares in the company, valued at approximately $37,256,069.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 281,108 shares of company stock worth $61,321,396. Corporate insiders own 1.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Wagner Wealth Management LLC Acquires New Position in Becton Dickinson and Co (BDX)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3299894/wagner-wealth-management-llc-acquires-new-position-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.